Amarin Corp Plc (AMRN)

[bogatie]

I understand that they have not heard anything about delay or an ADCOM. That does not mean that additional data since 28 March has been requested by or provided to the FDA. If Amarin failed to disclose that the FDA has requested additional data, especially in light of the public offering, I would say that information could destroy the company. Not disclosing that the FDA had asked for additional info in the prospectus would make the entire placement of the 22 million shares a sham, especially if an expanded label were denied.
For this reason, I hope that they have had no info requests (i.e. more data) from the FDA. Don't conflate that with delay or ADCOM info - they are not the same.

I remain optimistic that such data has not been requested. If it was, then Amarin's wording in the prospectus was written by the worst lawyers ever and I think their legal team is pretty darn sharp.